METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 67, Rue Saint Jacques, Paris,île-De-France 75005,france
- Industry
- Biotechnology
- Website
- https://methysdx.com/en/
- Keywords
- ctDNA, Cancer, Biomarqueurs, circulating tumoral DNA, Liquid biopsy, Precision medicine, ddPCR.
- HQ
- Paris, Île-de-France
Methys Dx Questions
Methys Dx's website is https://methysdx.com/en/
Methys Dx's LinkedIn profile is https://fr.linkedin.com/company/methys-dx
Methys Dx has
14 employees.
View email and phone details for 14
employees at Methys Dx.
Methys Dx's industry is
Biotechnology
Methys Dx's top competitors are
Pelican Health,
One Biosciences,
Embobio Medical,
Twinical,
Tafalgie Therapeutics,
Ais Biotech,
Signal Med +,
Neuroclues,
4moving Biotech,
Acusurgical.
Methys Dx's categories are Biotechnology
Methys Dx's founding year is 2021
